Login to Your Account

ACAAI Roundup

Tuesday, November 8, 2011

These items were presented at the American College of Allergy, Asthma and Immunology annual meeting (ACAAI):

• Baxter International Inc., of Deerfield, Ill., presented Phase III data that showed patients with primary immunodeficiencies had a reduced rate of serious bacterial infections when treated with HyQ, an investigational combination immunoglobulin product. The data also suggested the possibility for a three- or four-week dosing schedule with single-site, self-administered infusions. The prospective, open-label study enrolled 89 patients in Canada and the U.S.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription